SAB begins phase 1 trial of Covid-19 therapeutic candidate SAB-185
According to the company, SAB-185 is a fully-human, specifically targeted, and broadly neutralising polyclonal antibody therapeutic candidate. Besides potentially treating Covid-19 patients, the drug candidate can provide protective
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.